NEJM 3 26 26 Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

his clinical study investigates whether adding the immunotherapy drug atezolizumab to standard chemotherapy significantly benefits patients recovering from high-risk, stage III colon cancer with specific genetic deficiencies. Researchers compared a traditional drug cocktail against a combination treatment followed by extended immunotherapy to see if it could better prevent cancer recurrence. The results demonstrated that this dual approach markedly improved disease-free survival rates over three years, despite a noted increase in side effects. Ultimately, the text highlights a major advancement in personalized oncology, suggesting that targeting a tumor's specific molecular profile can lead to superior long-term outcomes